PDCD1 and liver cancer: In order to analyze the effect of HBV infection on anti-PD-1 therapy in non-liver cancer patients, a total of 35 HBV+ non-liver cancer patients were screened from 7,231 cancer patients who visited during 2018–2021 (Fig. 1A, Supplementary Fig. S1A, Supplementary Table 1).